Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company's profitability has significantly improved, with a projected revenue increase of 16.63% to 3.62 billion yuan in 2025 and a net profit growth of 222.30% to 421.3 million yuan [7] - The high-end scientific instrument industry is experiencing a recovery driven by favorable policies, and the company's high-end products are gaining market recognition [7] - The company plans to implement a simplified procedure for refinancing to enhance its competitive advantage [7] Financial Performance Summary - Total revenue forecast for 2024A is 310.26 million yuan, increasing to 630.40 million yuan by 2028E, with a compound annual growth rate (CAGR) of approximately 18.85% [1] - The net profit attributable to the parent company is expected to rise from 13.07 million yuan in 2024A to 78.08 million yuan in 2028E, reflecting a CAGR of about 20.89% [1] - The latest diluted EPS is projected to grow from 0.15 yuan in 2024A to 0.92 yuan in 2028E [1] Business Segment Analysis - The organic element analysis series is the largest revenue source, generating 113 million yuan in 2025, with a gross margin of 75.63% [7] - The chromatography and spectroscopy series saw a revenue increase of 20.60% to 95.18 million yuan, with a gross margin of 58.55% [7] - The sample pretreatment and general instruments series also showed strong growth, with revenue increases of 23.27% and 21.38%, respectively [7] Competitive Advantages - The company has established a solid foundation with key products like the Kjeldahl nitrogen analyzer and microwave digestion instrument, providing stable cash flow [7] - The company is entering the billion-level chromatography market, enhancing revenue elasticity with products that meet domestic and international standards [7] - A full industry chain operation model allows for high self-sourcing rates of key components, ensuring product quality and cost advantages [7]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company reported a significant increase in its performance, with a non-GAAP net profit growth of 821% year-on-year for 2025. The total revenue for the year reached 362 million yuan, representing a year-on-year growth of 16.63% [2][3] - The substantial profit increase is attributed to the recovery of the industry and the ramp-up of high-end product sales, supported by favorable policies and increased domestic demand for high-end scientific instruments [3] - The company has established a strong competitive position in the high-end scientific instrument sector, with a focus on innovative product development and efficient management practices [4] Financial Performance Summary - For 2025, the company achieved total revenue of 362 million yuan, a year-on-year increase of 16.63%, and a net profit attributable to shareholders of 42.12 million yuan, reflecting a 222.20% increase year-on-year. The non-GAAP net profit reached 35.57 million yuan, up 821.24% [2][3] - The company’s gross margin remained stable, and it effectively managed its expenses, contributing to a significant leap in profitability [3] - The projected net profits for 2025 to 2027 are 0.42 billion, 0.54 billion, and 0.65 billion yuan, respectively, with corresponding P/E ratios of 50, 39, and 32 times [4]